BI 894999: a selective inhibitor of the BET family
BI 894999* is an oral, potent and selective inhibitor of the bromodomain and extra-terminal (BET) family of bromodomain (BRD)-containing proteins.1–3
Clinical trials: BI 894999 is currently being investigated in a Phase I clinical trial in patients with advanced solid tumours.4
Role of BET proteins
BRD proteins are chromatin ‘readers’. They bind to and interpret post-translational modifications added by epigenetic ‘writers’ or removed by epigenetic ‘erasers’ and thereby regulate gene expression.5,6
BRD4 is a member of the BET family and is considered to be a key epigenetic regulator.1,2BRD4 controls a subset of genes by recognising key regulatory elements and indirectly modulating essential transcription factors, such as c-Myc and E2F.5 BRD4 deregulation is implicated in a number of haematological malignancies and solid tumours.6–11
About BI 894999
Mechanism of action
BI 894999 is an oral inhibitor of the BET family of BRD-containing proteins that bind to acetylated histones inducing transcription.1–3,12
BI 894999 inhibits BRD4 (as well as BRD2, BRD3 and BRDT) with high selectivity and potency, 1–3,12 triggering suppression of target gene transcription (e.g. the oncogene Myc). 5,6,13
Mechanism of action: inhibition of BRD42
Ac, acetyl group; BET, bromodomain and extra-terminal domain; BRD4, bromodomain protein 4; CDK9, cyclin-dependent kinase 9; CTD, C-terminal domain; P, phosphate; mRNA, messenger ribonucleic acid.
BI 894999 has shown high in vitro and in vivo activity in multiple myeloma, acute myeloid leukaemia and solid tumours.1–3
Initial data from a Phase I study (1367.1) of BI 894999 demonstrated clinical activity and a manageable safety profile in patients with solid tumours.3 It also established the maximum tolerated dose for continuous dosing.3 Further investigations of BI 894999 are now underway in patients with advanced, unresectable and/or metastatic solid tumours that have failed on, or are unsuitable for, conventional treatment.4
BET, bromodomain and extra-terminal domain; BOR, best overall response; CR, complete reponse; DLT, dose-limiting toxicity; MTD, maximum tolerated dose; ORR, objective response; PFS, progression-free survival; PK, pharmacokinetics; PR, partial response; PSA, prostate-specific antigen.
Tontsch-Grunt U, et al. Poster presented at AACR-NCI-EORTC 2015 (Abstract B79).
Tontsch-Grunt U, et al. J Clin Oncol 2016;34(Suppl. 15):11574.
Aftimos PG, et al. J Clin Oncol 2017;35(Suppl. 15):2504.
ClinicalTrials.gov. NCT02516553. https://clinicaltrials.gov/ct2/show/record/NCT02516553 (Accessed: November 2019).
Jung M, et al. Epigenomics 2015;7(3):487–501.
Zuber J, et al. Nature 2011;478(7370):524–8.
Fu LL, et al. Oncotarget 2015;6:5501–16.
Xu Y, Vakoc CR. Cold Spring Harb Perspect Med 2017;7:pii: a026674.
Filippakopoulos P, et al. Nature 2010;468:1067–73.
Delmore JE, et al. Cell 2011;146:904–17.
Shi J, Vakoc C. Molecular Cell 2014;54:728–36; 6.
Doroshow DB, et al. Ann Oncol 2017;28:1776–87.
Gerlach D, et al. Oncogene 2018;37(20):2687–701
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2019 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: November 2019
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue